Perspective Therapeutics (CATX) Q2 2026 earnings summary

Executive summary

• Advanced clinical-stage radiopharmaceutical programs, including VMT-α-NET progressing toward Phase 3 in neuroendocrine tumors, with regulatory engagement and site activation targeted for year-end 2026; VMT01 and PSV359 also advancing with encouraging interim data and ongoing enrollment.

• Expanded manufacturing capacity with new and planned facilities in Houston, Chicago (completion early 2027), Los Angeles (completion 2H 2027), and Somerset, NJ, supporting clinical and future commercial supply.

• Strengthened intellectual property portfolio with new patents in the U.S. and China, and secured key supply and equipment agreements.

• Appointed Paul Lyne, Ph.D., as Chief Science Officer in July 2026.

Financial highlights

• Cash, cash equivalents, and short-term investments totaled $236.9 million as of June 30, 2026, up from $145 million at December 31, 2025.

• Net loss was $26.8 million for Q2 2026, or $0.22 per share, compared to $21.5 million, or $0.29 per share, in Q2 2025; six-month net loss was $53.0 million, up from $39.7 million year-over-year.

• Research and development expenses rose to $21.5 million for Q2 2026 (up $4.9 million year-over-year); general and administrative expenses were $7.8 million.

• Operating cash outflow increased to $52.1 million for the first half of 2026, with $94.5 million used in investing activities and $164.5 million provided by financing activities.

• Interest income contributed $2.3 million in Q2 2026.

Outlook and guidance

• Cash position expected to fund planned operations and clinical milestones into late 2027; management anticipates significant increases in R&D and manufacturing expenses as programs advance.

• Additional capital will be required to achieve profitability and support future growth, with potential for further equity or debt financing.

• Phase 3 VMT-α-NET study site activation targeted for year-end 2026, pending regulatory feedback; next PSV359 clinical update planned in 2027.